Acurx Pharmaceuticals (ACXP) Competitors $1.93 +0.04 (+2.12%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.01 (+0.52%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. LTRN, TXMD, AEON, CELU, and VYNEShould you buy Acurx Pharmaceuticals stock or one of its competitors? MarketBeat compares Acurx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acurx Pharmaceuticals include Lantern Pharma (LTRN), TherapeuticsMD (TXMD), AEON Biopharma (AEON), Celularity (CELU), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry. ACXP vs. LTRNACXP vs. TXMDACXP vs. AEONACXP vs. CELUACXP vs. VYNEHow does Acurx Pharmaceuticals compare to Lantern Pharma?Lantern Pharma (NASDAQ:LTRN) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings. Which has more risk and volatility, LTRN or ACXP? Lantern Pharma has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, suggesting that its stock price is 309% less volatile than the broader market. Do analysts recommend LTRN or ACXP? Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 1,506.22%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders hold more shares of LTRN or ACXP? 28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to LTRN or ACXP? In the previous week, Lantern Pharma had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 5 mentions for Lantern Pharma and 2 mentions for Acurx Pharmaceuticals. Lantern Pharma's average media sentiment score of 1.26 beat Acurx Pharmaceuticals' score of 0.82 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acurx Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, LTRN or ACXP? Lantern Pharma is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$17.12M-$1.45N/AAcurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/A Is LTRN or ACXP more profitable? Acurx Pharmaceuticals' return on equity of -153.92% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -198.34% -129.08% Acurx Pharmaceuticals N/A -153.92%-101.69% SummaryAcurx Pharmaceuticals beats Lantern Pharma on 8 of the 13 factors compared between the two stocks.How does Acurx Pharmaceuticals compare to TherapeuticsMD?TherapeuticsMD (NASDAQ:TXMD) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation. Which has better valuation and earnings, TXMD or ACXP? TherapeuticsMD has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTherapeuticsMD$3.02M8.08-$570K$0.0635.17Acurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/A Is TXMD or ACXP more profitable? TherapeuticsMD has a net margin of 5.34% compared to Acurx Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TherapeuticsMD5.34% 0.32% 0.23% Acurx Pharmaceuticals N/A -153.92%-101.69% Do analysts recommend TXMD or ACXP? Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 1,506.22%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, TXMD or ACXP? TherapeuticsMD has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, suggesting that its share price is 309% less volatile than the broader market. Does the media prefer TXMD or ACXP? In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for TherapeuticsMD. Acurx Pharmaceuticals' average media sentiment score of 0.82 beat TherapeuticsMD's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment TherapeuticsMD Neutral Acurx Pharmaceuticals Positive Do insiders and institutionals have more ownership in TXMD or ACXP? 30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryTherapeuticsMD beats Acurx Pharmaceuticals on 9 of the 15 factors compared between the two stocks.How does Acurx Pharmaceuticals compare to AEON Biopharma?AEON Biopharma (NASDAQ:AEON) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends. Do insiders & institutionals hold more shares of AEON or ACXP? 22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is AEON or ACXP more profitable? AEON Biopharma's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AEON BiopharmaN/A N/A -994.63% Acurx Pharmaceuticals N/A -153.92%-101.69% Do analysts recommend AEON or ACXP? Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 1,506.22%. Given Acurx Pharmaceuticals' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than AEON Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, AEON or ACXP? Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAEON BiopharmaN/AN/A-$36.63M-$5.00N/AAcurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/A Does the media prefer AEON or ACXP? In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for AEON Biopharma. Acurx Pharmaceuticals' average media sentiment score of 0.82 beat AEON Biopharma's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment AEON Biopharma Neutral Acurx Pharmaceuticals Positive Which has more risk and volatility, AEON or ACXP? AEON Biopharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, suggesting that its share price is 309% less volatile than the broader market. SummaryAcurx Pharmaceuticals beats AEON Biopharma on 7 of the 13 factors compared between the two stocks.How does Acurx Pharmaceuticals compare to Celularity?Acurx Pharmaceuticals (NASDAQ:ACXP) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk. Do analysts recommend ACXP or CELU? Acurx Pharmaceuticals presently has a consensus price target of $31.00, indicating a potential upside of 1,506.22%. Celularity has a consensus price target of $6.00, indicating a potential upside of 567.71%. Given Acurx Pharmaceuticals' higher probable upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than Celularity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ACXP or CELU more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -153.92% -101.69% Celularity -345.45%N/A -77.94% Which has preferable valuation & earnings, ACXP or CELU? Acurx Pharmaceuticals has higher earnings, but lower revenue than Celularity. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/ACelularity$26.55M0.98-$91.72M-$3.33N/A Do institutionals & insiders believe in ACXP or CELU? 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to ACXP or CELU? In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Celularity. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 0 mentions for Celularity. Acurx Pharmaceuticals' average media sentiment score of 0.82 beat Celularity's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Positive Celularity Neutral Which has more volatility & risk, ACXP or CELU? Acurx Pharmaceuticals has a beta of -2.09, indicating that its share price is 309% less volatile than the broader market. Comparatively, Celularity has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. SummaryCelularity beats Acurx Pharmaceuticals on 7 of the 13 factors compared between the two stocks.How does Acurx Pharmaceuticals compare to VYNE Therapeutics?VYNE Therapeutics (NASDAQ:VYNE) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Do analysts rate VYNE or ACXP? Acurx Pharmaceuticals has a consensus target price of $31.00, indicating a potential upside of 1,506.22%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than VYNE Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals have more ownership in VYNE or ACXP? 83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer VYNE or ACXP? In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 2 articles in the media. VYNE Therapeutics' average media sentiment score of 1.50 beat Acurx Pharmaceuticals' score of 0.82 indicating that VYNE Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Acurx Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VYNE or ACXP more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets VYNE Therapeutics-4,726.21% -70.42% -63.46% Acurx Pharmaceuticals N/A -153.92%-101.69% Which has more risk & volatility, VYNE or ACXP? VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its share price is 309% less volatile than the broader market. Which has better valuation & earnings, VYNE or ACXP? Acurx Pharmaceuticals has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVYNE Therapeutics$570K39.66-$26.48M-$0.38N/AAcurx PharmaceuticalsN/AN/A-$7.97M-$4.05N/A SummaryVYNE Therapeutics and Acurx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition ExportMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.40M$3.33B$6.34B$12.29BDividend YieldN/A2.29%2.79%5.33%P/E Ratio-0.4818.5321.0925.40Price / SalesN/A289.80527.8178.77Price / CashN/A129.8244.1356.13Price / Book0.786.909.997.01Net Income-$7.97M$24.23M$3.55B$335.05M7 Day Performance-0.52%0.59%0.42%-0.29%1 Month Performance-16.81%-0.61%-0.05%1.15%1 Year Performance-76.52%63.26%35.06%34.79% Acurx Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.3925 of 5 stars$1.93+2.1%$31.00+1,506.2%-77.2%$5.40MN/AN/A3LTRNLantern Pharma1.0723 of 5 stars$2.06-1.4%N/A-8.9%$23.30MN/AN/A20Positive NewsEarnings ReportTXMDTherapeuticsMD0.5444 of 5 stars$1.95-0.5%N/A+39.6%$22.56M$3.02MN/A420Positive NewsAEONAEON Biopharma0.9488 of 5 stars$0.89+0.6%N/A+69.6%$22.44MN/A4.935Gap UpCELUCelularity1.2102 of 5 stars$0.78+0.8%$6.00+672.7%-64.6%$22.39M$26.55MN/A220Gap Up Related Companies and Tools Related Companies Lantern Pharma Alternatives TherapeuticsMD Alternatives AEON Biopharma Alternatives Celularity Alternatives VYNE Therapeutics Alternatives Anebulo Pharmaceuticals Alternatives Exicure Alternatives Quince Therapeutics Alternatives Quantum Biopharma Alternatives Pasithea Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
